Decision on optimal combinatorial Therapies in IMIDS using Systems Approaches

Project Overview

DoCTIS is an EU-funded translational project aimed at addressing the urgent need to discover effective therapeutic strategies for immune-mediated inflammatory diseases.

Partners

Biomedical research partners from five different European countries as well as from the United States of America are collaborating toward this.

Work Packages

The DoCTIS project is structured in nine different work packages, involving animal model, patient, systems biology and clinical evaluation stages.

ABOUT DocTIS

DoCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches”. DoCTIS is a multicentric project involving diverse basic, applied and clinical research centres from Spain, Sweden, Italy, Germany, UK and USA aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis. Through the generation of high volumes of data using of modern high-throughput technologies on samples from well-characterized IMID patients, and the use of advanced systems biology analytical approaches, we aim to identify therapeutic combinations that are much more efficacious and safer than current single-drug approaches.

MEDIA CENTER


Follow the most recent activity generated from the DoCTIS project.

News

See DoCTIS in the media and published work derived from the project.

Events

Calendar of future and past events associated to the DoCTIS project.

Patients

If you are a patient suffering from an IMID, click here to know more on how the research at the DoCTIS project is working to help you.

#DoctisEU partners @IMIDomics and @VHIR_ extend previous identification of #abatacept as drug therapy for severe #COVID19 and develop a transcriptomic biomarker signature https://www.nature.com/articles/s41598-021-90797-0

.@xiliotx Collaborates With @Merck to Evaluate Combo of CTLA-4 and PD-1 Blockers Against Solid Tumors

#Cancer #immunotherapy #combinationtherapy #antibody #GeneOnline

https://geneonline.news/en/xilio-collaborates-with-merck-to-evaluate-combo-of-ctla-4-and-pd-1-blockers-against-solid-tumors/

Using personalized medicine to overcome leukemia treatment resistance #combinationtherapy https://bionewscentral.com/using-personalized-medicine-to-overcome-leukemia-treatment-resistance/

Not everyone responds to #immunotherapy the same way. Many #clinicaltrials are designed to find combinations of drugs that overcome the limitations in #targeted therapy. https://buff.ly/2F6CNra #melanoma #combinationtherapy

#doctis partner Prof Britta Siegmund participates in study evaluating #combinationtherapy in #IBD:
Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis
https://academic.oup.com/ibdjournal/advance-article-abstract/doi/10.1093/ibd/izab063/6224889

Load More…